UltraPlex EPA is a cutting-edge supplement formulated with MaxSimil® monoglyceride fish oil, designed to maximize the benefits of omega-3 fatty acids. Featuring a highly bioavailable delivery system, UltraPlex EPA supports cardiovascular health, cognitive function, healthy glucose metabolism, and much more. With its patented lipid absorption enhancement technology, it provides superior EPA and DHA absorption, ensuring greater effectiveness with every dose.
MaxSimil® Patented Lipid Absorption Enhancement Technology (PLATform) is the secret behind UltraPlex EPA's enhanced bioavailability. This unique monoglyceride fish oil delivery system bypasses the body’s normal fat digestion process, ensuring rapid and efficient absorption of EPA and DHA. MaxSimil technology is particularly beneficial for individuals with digestive challenges, such as those with pancreatic or gall bladder concerns, as it optimizes nutrient uptake without the need for extensive digestion.
Studies show that MaxSimil fish oils provide 300% greater absorption of EPA and DHA compared to leading fish oils, making UltraPlex EPA an unparalleled choice for those seeking high-potency omega-3 supplementation.
In Vitro & In Vivo Animal Studies – Research has demonstrated that MaxSimil-enhanced EPA and DHA support growth inhibition and apoptosis (cell death) in various diseased cell lines, including colorectal, breast, lung, and prostate cancer cells. These studies have shown that the superior bioavailability of MaxSimil-enhanced EPA and DHA translates into enhanced therapeutic effects.
Preclinical Bioavailability Studies – Pharmacokinetic studies in rodents revealed that MaxSimil DHA fish oil provides three times higher absorption compared to traditional ethyl ester (EE) DHA oil. This superior bioavailability ensures that your cells receive optimal exposure to the beneficial effects of DHA and EPA.
